جست‌وجوی استاد و پژوهشگر

DaeYong Leeمشاهده پروفایل

استادیار

• Cancer Immunotherapy
• Biomaterials
• Nanomaterials
• +۷ مورد دیگر

DaeYong Lee, Ph.D., is an Assistant Professor at the Fralin Biomedical Research Institute at VTC and the Department of Biomedical Engineering and Mechanics in the College of Engineering at Virginia Tech. His research is centered in the Cancer Research Center – Roanoke, where he leads the Lee Lab focused on developing novel biomaterials to enhance cancer immunotherapy. Research Interests: Dr. Lee's work lies at the intersection of biomedical engineering, immunology, and materials science. He develops synthetic biomaterials—particularly cationic helical polypeptides and nanobioconjugates—to re-educate immune cells within tumor microenvironments, overcoming immune exhaustion and enhancing antitumor responses. His research emphasizes translational approaches to improve the accessibility and affordability of immunotherapies, with a current focus on breast cancer. Recent Research Trends: His recent publications in top journals like Nature Biomedical Engineering and Nature Nanotechnology highlight a strong trajectory in engineering nanomaterials with tunable physical properties for immune modulation, understanding age-related disparities in nanotherapeutic efficacy, and designing biomaterials that activate innate immunity. These works reflect a cohesive focus on making immunotherapies more universal and effective across diverse patient populations. Poster presentation award, Leading Edge of Cancer Research Symposium, University of Texas MD Anderson Cancer Center, 2023 American Association for Cancer Research (AACR)-Sygnature Discovery Scholar-in-Training Award, 2023 Top 5 Research Achievement in the Field of Biotechnology in South Korea, BRIC, 2019 Postdoctoral Fellowship, National Research Foundation in Korea, 2018-2019 Poster presentation award, The Korean Society for Biomaterials, 2014 Advising and Grants: As a new faculty member supported by the Red Gates Foundation through the Fralin Biomedical Research Institute, Dr. Lee is building his research team and lab infrastructure. While student advisees are not yet listed, he is expected to mentor graduate students and postdoctoral researchers in interdisciplinary cancer research. His work builds on strong foundational training and has already attracted recognition from major cancer research organizations. Labs and Teams: Dr. Lee leads the Lee Lab at the Cancer Research Center – Roanoke, part of the Fralin Biomedical Research Institute. His team collaborates across disciplines to engineer next-generation immunotherapeutics, leveraging Virginia Tech’s state-of-the-art facilities and collaborative environment.

Xin Liuمشاهده پروفایل

استادیار

• Immunometabolism
• Innate Immunity
• Host-Pathogen Interactions
• +۷ مورد دیگر

Xin Liu, PhD is an Assistant Professor in the Department of Biochemistry at the School of Medicine, Case Western Reserve University. Their research focuses on the intersection of immunology and metabolism, particularly in the context of lung infections and cancer. Research Interests: The lab investigates how metabolic pathways regulate the function of innate immune cells such as macrophages and monocytes. Specific areas include metabolic reprogramming during infection, host factor roles in immune modulation, and cell-cell communication at the immune-metabolic interface. The overarching goal is to manipulate immune-metabolic networks to improve treatments for infectious diseases and cancer. Publication Trends: Dr. Liu's recent work, published in journals like Cell Host & Microbe and The Journal of Immunology , centers on innate immune responses to pathogens such as Legionella and influenza viruses, with a strong emphasis on metabolic regulation and signaling pathways including RIG-I and MyD88. Scientific Awards: No awards mentioned in the provided text. Advising and Grants: While no specific students or grants are listed, Dr. Liu leads an independent research laboratory focused on immunometabolism. Their work likely involves extramural funding, though details are not provided. Labs and Teams: Dr. Liu directs a research lab that studies immunometabolic regulation in disease contexts, collaborating with experts in microbiology, immunology, and pulmonary biology.

Vincenzo Cerulloمشاهده پروفایل

استاد

• Immunotherapy
• Cancer Therapy
• Gene Therapy
• +۴ مورد دیگر

Roles and Affiliations: Vincenzo Cerullo is a Professor at the Faculty of Pharmacy, University of Helsinki , leading the ImmunoViroTherapy Lab within the Division of Pharmaceutical Biosciences. He supervises doctoral programs in Integrative Life Science, Biomedicine, and Drug Research. He holds adjunct roles in experimental virology and has served as Principal Investigator and group leader in molecular cancer biology. Education: He earned a Master of Pharmacy (1998) and PhD in Biotechnology (2004) from the University of Naples and University of L’Aquila. He became a Docent in Experimental Virology at the University of Helsinki (2011). Research Focus: His work centers on Immunovirotherapy , combining oncolytic viruses with immunomodulatory strategies to combat cancer. Key areas include: Oncolytic Adenoviruses : Engineering viruses to enhance tumor targeting and immune activation. Cancer Vaccines : PeptiCRAd platform for personalized vaccines using peptide-coated vectors. Epigenetic Therapy : Synergizing with viral vectors to improve treatment efficacy. Clinical Translation : Bridging preclinical models (e.g., murine melanoma) to human trials. Recent Research Trends: Articles emphasize high-throughput viral titering , PD-L1 modulation via PNA , and selenium nanoparticle synergies . Themes include precision medicine, immune checkpoint inhibition, and combinatorial therapies. Awards & Recognition: 2012: New Investigator of the Month (ASGT) 2014: Outstanding Young Investigator (ESGCT) 2013: Nomination for ASGCT’s Outstanding New Investigator 1999: Società Chimica Italiana Award for Master’s Thesis Grants & Leadership: Secured over €1.2M in grants from Sigrid Jusélius Foundation, Business Finland, and Cancer Foundation Finland. Supervised 6 PhD candidates and mentored 4 master’s students. Led projects on mesothelioma treatment, viral vaccine development, and personalized oncology. Labs & Collaborations: Directs the ImmunoViroTherapy Lab, collaborating internationally with Baylor College of Medicine (USA), University of Verona (Italy), and national partners like Akseli Hemminki at the University of Helsinki.

Chandrabali Bhattacharyaمشاهده پروفایل

استادیار

• Organic Chemistry
• Glycochemistry
• Glycobiology
• +۵ مورد دیگر

Chandrabali Bhattacharya serves as Assistant Professor in the Department of Chemistry and Biochemistry at the University of Nevada, Las Vegas, where she founded and directs the mRNA Nanomedicine Program to advance mRNA therapeutics research in Nevada. Her work pioneers targeted delivery systems for mRNA using carbohydrate-protein interaction principles. Dr. Bhattacharya earned bachelor's and master's degrees in chemistry from Presidency College Kolkata and Indian Institute of Technology Kharagpur. She completed her Ph.D. in bioorganic chemistry at Arizona State University under Dr. Sidney M. Hecht, investigating bleomycin's disaccharide moiety in tumor targeting. Subsequent postdoctoral training included glycosaminoglycan research with Dr. Linda Hsieh-Wilson at Caltech and mRNA delivery development with Drs. Daniel Anderson and Robert Langer at MIT's Koch Institute as a Juvenile Diabetes Research Foundation Fellow. Her research integrates organic chemistry, glycobiology, and nanomedicine to design precision mRNA delivery vehicles. The Bhattacharya Lab specializes in glycolipid-based nanoparticles that target immune cells for cancer immunotherapy, including CAR-T cell engineering and personalized neoantigen vaccines. By leveraging disease-specific glycation patterns, her team develops 'living drugs' through reprogrammed T cells and dendritic cell-targeted vaccines. Analysis of her 2024-2025 publications reveals groundbreaking work in expanding mRNA delivery beyond liver/lung targets. Key innovations include Cortico LNPs for spleen-selective delivery (enabling autoimmune disease treatments) and ENDO LNPs for pancreatic targeting (with implications for diabetes and pancreatic cancer therapies). Her research consistently bridges fundamental glycochemistry with clinical translation in oncology and immunology. Her scientific recognition includes: Juvenile Diabetes Research Foundation Fellowship Supported by competitive research funding, Dr. Bhattacharya leads a multidisciplinary team developing next-generation delivery platforms. Her mRNA Nanomedicine Program fosters statewide collaboration to position Nevada as a hub for RNA therapeutics innovation, with current projects focused on overcoming tissue-specific delivery barriers for cancer and metabolic diseases. The Bhattacharya Lab operates at the chemistry-biology-engineering interface, combining synthetic organic chemistry with cellular immunology to solve delivery challenges. Future work will expand organ-targeting capabilities and accelerate clinical translation of mRNA-based cancer immunotherapies through industry partnerships and novel biomaterial design.

Alisha Holtzhausen Hanksمشاهده پروفایل

استادیار

• Tumor Immunology
• Cancer Immunotherapy
• TAM RTK Signaling
• +۵ مورد دیگر

Alisha Holtzhausen Hanks, PhD is an Assistant Professor in the Department of Pharmacology at the University of North Carolina at Chapel Hill School of Medicine. Her research is conducted at the Lineberger Comprehensive Cancer Center, where she maintains her laboratory at 540 West St., 21-235 Lineberger Cancer Center, Chapel Hill, NC. Dr. Hanks' work bridges basic immunological mechanisms with translational cancer research, focusing on improving immunotherapeutic outcomes for cancer patients. Dr. Hanks' research focuses on tumor immunology and immunotherapy, with particular emphasis on the interplay between the immune system and tumor cells. Her laboratory investigates mechanisms governed by TAM receptor tyrosine kinases (Tyro3, Axl, MerTK) that suppress immune responses to tumors. Additionally, her team explores how myeloid cells contribute to adaptive resistance to immunotherapy, seeking to identify novel targets to enhance current immunotherapeutic approaches. Her work spans multiple immune cell types including dendritic cells, macrophages, and myeloid-derived suppressor cells within the tumor microenvironment. Analysis of Dr. Hanks' publication record reveals a consistent focus on understanding the molecular mechanisms of tumor immune evasion and resistance to immunotherapy. Her work spans multiple areas including dendritic cell function, macrophage polarization, TAM receptor signaling, and metabolic reprogramming within the tumor microenvironment. A recurring theme in her research is identifying how tumor-intrinsic signaling pathways create immunosuppressive microenvironments that limit the efficacy of current immunotherapies like anti-PD-1 treatment. Her most recent work (2024) continues to explore MerTK-induced dysfunctional dendritic cells through metabolic reprogramming and MERTK inhibition as a targeted cancer therapy. Dr. Hanks has established herself as a productive researcher in the field of cancer immunology, with publications in high-impact journals including Cancer Immunology Research, Science Immunology, Science Translational Medicine, Nature Communications, and Journal of Clinical Investigation. Her collaborative approach is evident through her extensive co-authorship network across multiple institutions, including prominent UNC researchers like H. Shelton Earp and Brent Hanks. While specific information about her advising activities is limited in the provided materials, Dr. Hanks appears to be actively involved in mentoring graduate students and postdoctoral fellows in her laboratory. Her research program likely receives funding from multiple sources including the National Institutes of Health and cancer-focused foundations, though specific grant details are not provided in the available information. Her work often involves translational approaches connecting basic molecular mechanisms with potential clinical applications. Dr. Hanks' laboratory is situated within the Lineberger Comprehensive Cancer Center at UNC Chapel Hill, a National Cancer Institute-designated comprehensive cancer center. This positions her research within a collaborative environment with access to clinical samples, patient data, and translational research infrastructure that supports her investigations into cancer immunology and immunotherapy resistance mechanisms. Her research has important implications for developing combination therapies that can overcome resistance to current immunotherapies, potentially improving outcomes for cancer patients.

Lionel B Ivashkivمشاهده پروفایل

استاد

• Autoimmunity
• Inflammatory diseases
• Cytokine signaling
• +۷ مورد دیگر

Lionel B Ivashkiv, MD , is Professor of Medicine and Immunology at Weill Cornell Medical College and Chief Scientific Officer at the Hospital for Special Surgery (HSS) , positions he has held since 1992. His dual affiliation places him at the forefront of translational research in autoimmune and inflammatory diseases. Education: MD, Harvard Medical School (1984) BA, Columbia University (1980) Research Focus: Dr. Ivashkiv's laboratory investigates cytokine-mediated pathogenesis in autoimmune, inflammatory, and musculoskeletal diseases. His work centers on the regulation of cytokine signaling, gene transcription, and epigenomic control of myeloid cells, osteoclasts, and synovial fibroblasts in diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory osteolysis. He employs cutting-edge techniques including RNA-seq, ChIP-seq, ATAC-seq, and CRISPR-Cas9 genome editing to dissect molecular mechanisms and identify precision medicine approaches. Recent Trends in Publications: His recent work spans from epigenetic reprogramming of macrophages and monocytes to translational models of implant failure and fibrosis. Key themes include the interplay between TNF, IFN-γ, and IL-10 in shaping inflammatory responses, the role of epigenetic modifiers like EZH2 and KDM1A in osteoclastogenesis, and the development of computational tools for musculoskeletal pathology. Grants & Collaborations: Dr. Ivashkiv's research is supported by multiple NIH and foundation grants. He collaborates extensively with clinicians and engineers at HSS and Weill Cornell, and serves as a consultant to Eli Lilly and Company, translating his findings into therapeutic strategies for inflammatory diseases. Laboratory & Teams: His lab integrates basic science with translational medicine, working closely with orthopedic surgeons, rheumatologists, and bioinformaticians. The team focuses on identifying druggable targets in cytokine and epigenetic pathways to modulate inflammation and tissue damage in autoimmune diseases.

Ivana Bjelobabaمشاهده پروفایل

پژوهشگر

• Neurobiology
• Neuroendocrinology
• Neuroinflammation
• +۴ مورد دیگر

Dr. Ivana Bjelobaba is a Principal Research Fellow at the Department of Neurobiology, Institute for Biological Research "Siniša Stanković," which is a National Institute of the Republic of Serbia affiliated with the University of Belgrade. Her research focuses on neurobiology, neuroendocrinology, and neuroinflammation, with particular expertise in experimental autoimmune encephalomyelitis and purinergic signaling. Her primary research interests include: Neuroendocrine regulation during autoimmune conditions Purinergic signaling pathways in neuroinflammation Effects of experimental autoimmune encephalomyelitis (EAE) on hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes Sex-specific differences in neuroendocrine-immune interactions Metabolic changes in microglia during inflammatory conditions Neuroprotective strategies including hyperbaric oxygenation Dr. Bjelobaba's recent publication record demonstrates a consistent focus on the bidirectional relationship between the nervous and immune systems. Her work has significantly advanced understanding of how autoimmune disorders affect neuroendocrine function and how neuroendocrine changes modulate immune responses. She has made notable contributions to characterizing purinergic signaling alterations during EAE progression and identifying potential therapeutic targets like agmatine that modulate microglial metabolism and inflammatory responses. Her research employs diverse methodologies including: Rodent models of autoimmune disease (particularly Dark Agouti rats) Molecular and cellular techniques to study signaling pathways Neuroanatomical and histological analyses Metabolic profiling of brain cells Therapeutic interventions including pharmacological agents and hyperbaric oxygenation Dr. Bjelobaba's work bridges basic neuroscience with potential clinical applications for neurological conditions with autoimmune components, contributing significantly to the understanding and potential treatment of disorders like multiple sclerosis.

• Atherosclerosis
• Cardiovascular Disease
• Macrophage Biology
• +۳ مورد دیگر

Professor Erik Biessen is a cardiovascular research scientist affiliated with the Institute for Molecular Cardiovascular Research (IMCAR). His work focuses on molecular mechanisms underlying atherosclerosis, macrophage biology, lipid metabolism, and inflammation. He leads studies on proteoglycan signaling, chemokine networks, and metabolic reprogramming in cardiovascular pathologies. Key Research Areas Atherosclerosis mechanisms and plaque vulnerability Macrophage heterogeneity in cardiovascular disease Lipidomics and uremic toxin interactions Role of microRNAs and metabolic networks Recent Article Trends Studies on cathepsin D inhibition in liver lipidomics (2025) MicroRNA-26b's protective role in MASH (2025) Investigations into glutamine metabolism's impact on plaque inflammation (2024) Chemokine CCL18's role in T-cell infiltration (2024)

Renato Ostuniمشاهده پروفایل

دانشیار

• Immunology
• Genomics
• Molecular Biology
• +۳ مورد دیگر

Renato Ostuni is an Associate Professor at Vita-Salute San Raffaele University and leads the Unit of Innate Immune System Genomics at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget). His research focuses on immunology, genomics, and inflammation in cancer and disease contexts. He is affiliated with the School of Medicine. Ph.D. in Translational and Molecular Medicine (2008-2010), Università di Milano-Bicocca Specialized in Industrial Biotechnology (2005-2007), Università di Milano-Bicocca Bachelor’s in Biotechnology (2002-2005), Università di Milano-Bicocca His research explores macrophage and neutrophil dynamics , tumor microenvironment reprogramming, and neurotoxic inflammation mechanisms. Recent work includes CRISPR-based T-cell engineering and DNA damage in neuroinflammatory diseases. His publications span top-tier journals like Science , Nature , and Cell , with a focus on immunology, cancer research, and regenerative medicine. Key collaborators include Gioacchino Natoli and Ido Amit. Scientific Awards: Alessandro Moretta Young Investigator Award (2019) Young Investigator Award, European Macrophage and Dendritic Cell Society (2018) ERC Starting Grant (2017) LaboSpace Prize (2017) Bioeconomy Rome Award (2013) EMBO Short-Term Fellowship (2012) He has served as an Associate Editor for Frontiers in Immunology and reviewed for journals like Nature Immunology and Cell Reports , alongside grant evaluations for the Italian Ministry of Health and European Research Council.

Lorenzo Piemontiمشاهده پروفایل

دانشیار

• Diabetes
• Endocrinology
• Regenerative Medicine
• +۶ مورد دیگر

Lorenzo Piemonti serves as Associate Professor of Endocrinology at Vita Salute San Raffaele University in Milan, Italy, and holds key leadership positions at the San Raffaele Scientific Institute where he directs the Diabetes Research Institute and the Department of Regenerative Medicine and Transplantation. He previously served as Visiting Professor at Vrije Universiteit Brussels (2016-2022) and will serve as President of the International Pancreas and Islet Transplantation Association (IPITA) for 2025-2027. His research focuses on diabetes pathophysiology, beta cell biology, and regenerative medicine approaches to diabetes treatment. Key areas include beta cell replacement therapies, immune tolerance induction strategies, stem cell differentiation for insulin-producing cells, and the development of biomaterials to support islet transplantation. He has pioneered work in dendritic cell biology related to diabetes autoimmunity and has significant contributions to pancreatic oncology research. Dr. Piemonti's recent publications demonstrate a strong focus on translational research bridging basic science discoveries with clinical applications, particularly in islet transplantation outcomes, stem cell-derived beta cells, immune tolerance strategies, and precision medicine approaches to diabetes classification and treatment. Premio Alcmeone (2012) from Società Italiana di Diabetologia Premio per Giovani Ricercatori (2005) from Fondazione Guido Berlucchi As a physician-scientist, Dr. Piemonti maintains active editorial roles as Section Editor for Cell Transplantation and Associate Editor for Transplant International and Journal of Endocrinological Investigation. His leadership extends to multiple international committees including the European Pancreas and Islet Transplant Registry steering committee and various roles within IPITA. He coordinates the European Consortium for Islet Transplantation, which has provided human beta cell products for research and clinical applications across Europe since 2000. His laboratory maintains active collaborations across multiple European institutions through the European Consortium for Islet Transplantation and participates in numerous clinical trials related to beta cell replacement therapies and immune interventions for diabetes.

• Immunology
• Allergy and Asthma Research
• Dendritic Cell Biology
• +۳ مورد دیگر

Dr. John Gordon is a Professor at the College of Medicine , University of Saskatchewan , specializing in translational immunology . His research focuses on harnessing dendritic cells to suppress hyper-sensitive immune responses, with breakthrough applications in asthma , food allergies , and autoimmune diseases . He leads the Respiratory Research Centre, emphasizing collaborative strategies to advance immunotherapeutic solutions for respiratory conditions affecting millions of Canadians. Therapeutic Innovation: Reprogrammed dendritic cells reduce airway inflammation by 90% in preclinical models. Clinical Translation: Work extends to autoimmune diseases like Multiple Sclerosis via regulatory T cell mechanisms. Collaborative Vision: Advocates for resource-sharing through the Respiratory Research Centre to accelerate scientific breakthroughs. His publications span chemokine antagonism , dendritic cell therapy , and inflammatory disease models , with key contributions to allergy immunology and cancer treatment. Current efforts involve clinical trials for allergen-specific tolerance induction and interdisciplinary exploration of respiratory health challenges.

Han Seong-rimمشاهده پروفایل

استاد

• Immunonutrition
• Clinical Nutrition
• Immunometabolism
• +۳ مورد دیگر

Han Seong-rim is a Professor at the Department of Food and Nutrition, College of Human Ecology, Seoul National University. With a PhD from Tufts University, her research focuses on immunonutrition and clinical nutrition, particularly examining how vitamins and obesity influence immunometabolism, immune cell function, and chronic disease prevention. Her laboratory investigates: The impact of genetic information awareness on dietary and health behaviors Vitamin D’s role in immunometabolism across metabolic diseases Obesity’s influence on vitamin D metabolism and immune function Dr. Han’s 2024-2025 publications reveal a consistent focus on vitamin D’s immunomodulatory effects in diabetic and obese mouse models, with emphasis on dendritic cells, T cells, and adipose tissue. Her work appears in journals like Nutrition Research , Nutrients , and Journal of Nutritional Biochemistry . Notable scientific awards include: JLA Excellence Award (2023) Minister of Health and Welfare Commendation (2019) NRP Most Cited Award (2019) Korean Society of Community Nutrition Academic Award (2012) She has served as President of the Korean Nutrition Society (2023) and Korean Society of Clinical Nutrition (2021), and delivered invited lectures at international symposia including ICoLA2024 and APPSPGHAN 2023 .

• Neuro-oncology
• Glioblastoma Immunotherapy
• Molecular Pharmacology
• +۳ مورد دیگر

Linda Liau, M.D., Ph.D., is a Professor in the Department of Neurosurgery at the University of California, Los Angeles (UCLA). She holds affiliations with the Brain Research Institute, Jonsson Comprehensive Cancer Center (JCCC), and multiple graduate programs including Molecular & Medical Pharmacology, Neuroscience, and Tumor Immunology. Her primary research focuses on glioblastoma pathogenesis and novel therapeutic strategies. Dr. Liau's research integrates molecular oncology, immunology, and advanced neuroimaging to develop precision therapies for brain tumors. Key interests include: Immunotherapeutic approaches (dendritic cell vaccines, immune checkpoint modulation) Metabolic reprogramming in gliomas (IDH mutations, lipid metabolism) Tumor microenvironment dynamics (neurovascular interactions, immune evasion) Epigenetic regulation of tumor progression Advanced MRI techniques for treatment response assessment Her recent publications demonstrate a strong emphasis on translational neuro-oncology, with recurring themes of immunotherapy resistance mechanisms, metabolic vulnerabilities in glioblastoma, and innovative imaging biomarkers. The majority of her work utilizes clinical trial data, molecular profiling, and preclinical models to bridge laboratory discoveries with patient care. Dr. Liau leads significant clinical trials, including phase 3 studies of autologous tumor lysate-loaded dendritic cell vaccines for glioblastoma. She also contributes to neurosurgical education and diversity initiatives, exemplified by her involvement in virtual symposia to promote inclusivity in neurosurgery.

• Bacterial Pathogenesis
• Immunology
• Host-Pathogen Interactions
• +۷ مورد دیگر

Adrianus (Ando) Van Der Velden is an Associate Professor in the Department of Microbiology and Immunology at Stony Brook University. He is affiliated with the Center for Infectious Diseases and maintains an active research laboratory focused on host-pathogen interactions, particularly with Salmonella . His work integrates immunology, microbiology, and host defense mechanisms to understand infectious disease processes. Department of Microbiology and Immunology, Stony Brook University Center for Infectious Diseases 240 Centers for Molecular Medicine, Stony Brook, NY Dr. Van Der Velden earned his Ph.D. in Molecular Microbiology and Immunology from Oregon Health and Science University in 2000. He completed postdoctoral training with Dr. Michael Starnbach at Harvard Medical School before joining Stony Brook University as an Assistant Professor (tenure-track) in 2008. He was promoted to Associate Professor with tenure in 2015. Dr. Van Der Velden's research primarily focuses on host interactions with Salmonella , with emphasis on immunological aspects of infection. His laboratory investigates two major thematic areas: the role of inflammatory monocytes in immunity and host defense against Salmonella , and the mechanisms by which Salmonella inhibits T cell responses. His work has revealed how Salmonella exploits inflammatory monocytes to promote its expansion in the inflamed intestine through nitrate-dependent mechanisms, and how bacterial asparagine hydrolase inhibits T cell responses by causing asparagine deprivation. His research provides critical insights into the complex interplay between pathogens, host immune responses, and gut microbiota. Analysis of Dr. Van Der Velden's recent publications reveals a consistent focus on Salmonella pathogenesis and host immune responses, with particular emphasis on monocyte function, T cell suppression mechanisms, and nutritional immunity. His work spans from basic molecular mechanisms of bacterial virulence to translational aspects of infection control. Recent publications increasingly incorporate broader immunological concepts, including connections to cancer immunology and mucosal immunity. The research demonstrates sophisticated integration of in vivo infection models with detailed cellular and molecular immunological approaches. Dr. Van Der Velden actively mentors graduate students and has hosted rotation students in his laboratory. While specific grant information isn't detailed in the provided text, his sustained research output suggests successful grant funding from agencies supporting infectious disease and immunology research. His laboratory appears to maintain collaborations across multiple institutions, as evidenced by co-authorship patterns in his publications. The Van Der Velden laboratory is situated within Stony Brook University's research infrastructure, with facilities in the Centers for Molecular Medicine. His work appears to integrate with Stony Brook's broader infectious disease research community through the Center for Infectious Diseases. The laboratory maintains active research programs investigating host-pathogen interactions using sophisticated murine infection models and advanced immunological techniques.

Beth Garvyمشاهده پروفایل

استاد

• Immunology
• Microbiology
• Pulmonary Immunology
• +۵ مورد دیگر

Beth Garvy, PhD is a Professor and Senior Associate Dean for Biomedical Education at the University of Kentucky College of Medicine. She holds appointments in the Department of Microbiology, Immunology, and Molecular Genetics and the Office of Biomedical Education, and serves as an MD/PhD Program Mentor. Dr. Garvy received her B.A. in Biology and Science Education from the University of South Florida (1981), M.A. in Exercise Physiology from The Ohio State University (1985), and Ph.D. in Biochemistry and Exercise Science from Michigan State University (1991). She completed postdoctoral training at the University of Miami School of Medicine (1993) and served as a Research Associate at the Trudeau Institute (1996). Her research focuses on pulmonary immunology, particularly the immune response to Pneumocystis carinii, an opportunistic fungal pathogen that causes pneumonia in immunosuppressed individuals. She has investigated how different life forms of P. carinii interact with the lung immune system and how neonatal mice handle respiratory infections. Currently, she is involved in the RECOVER project, a large NHLBI-funded clinical trial examining long-COVID, with specific interest in monocyte/macrophage interactions with virus, platelets, and coagulation factors. Her educational efforts include funding the Alliance of Biomedical Educators (ABE) to support faculty writing education program grants. Dr. Garvy's recent publications reflect a shift toward thrombosis research in viral infections, particularly HIV and long-COVID, while maintaining her expertise in pulmonary immunology and fungal pathogenesis. Her work demonstrates a progression from basic immunological studies of Pneumocystis to translational research on viral complications and thrombotic events. Notably, Dr. Garvy indicates that her administrative position as Senior Associate Dean for Biomedical Education occupies most of her time, and she is no longer training students or post-docs in a laboratory setting. She has received funding for the Alliance of Biomedical Educators to support educational grant writing among faculty in the College of Medicine. Her laboratory work historically focused on neonatal immunity, macrophage function, and host-pathogen interactions in the lung, with a particular emphasis on the differential immune responses to various life cycle stages of Pneumocystis organisms.